Related Experiment Video
Updated: Jan 26, 2026
06:05
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
1.6K
Update on ERbeta.
Jan-Ake Gustafsson1, Anders Strom1, Margaret Warner1
1Department of Biology and Biochemistry, University of Houston, Houston, Texas, United States.
The Journal of Steroid Biochemistry and Molecular Biology
|April 18, 2019
Summary
Despite evidence for estrogen receptor beta (ERβ) in epithelial proliferation, neurodegeneration, and immune function, ERβ agonists face clinical and research acceptance challenges. This paper examines reasons for the non-acceptance of ERβ
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Estrogen receptor beta (ERβ) has known roles in epithelial proliferation, neurodegeneration, and immune function.
- Despite synthesized ERβ agonists and ongoing clinical trials for prostate cancer and schizophrenia, none have reached clinical approval.
- Research and clinical acceptance of ERβ's value remains limited.
Purpose of the Study:
- To discuss the reasons behind the limited clinical and research acceptance of ERβ.
- To address criticisms and challenges faced by ERβ research.
Main Methods:
- Literature review and critical analysis of existing data.
- Discussion of counterarguments and challenges presented by research labs.
- Examination of the physiological and pathological roles of ERβ.
Main Results:
- Overwhelming data support ERβ's role in key physiological processes.
- Significant obstacles exist in the clinical translation and research community's acceptance of ERβ.
- Specific examples of grant review criticisms highlight the non-acceptance issue.
Conclusions:
- The non-acceptance of ERβ's value is multifaceted and requires further investigation.
- Addressing the identified issues is crucial for advancing ERβ-targeted therapies.
- Continued research and open discussion are needed to overcome current barriers.
